Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 19/20 | 0.62 |
| ▸ | GSK3B | P49841 | 1/20 | 0.62 |
| ▸ | PRKDC | P78527 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2483511 | 0.90 | ATR (0.76) | ATRGSK3BPRKDC | |
| SCHEMBL2482117 | 0.90 | ATR (0.66) | ATRGSK3BPRKDCKCNH2 | |
| SCHEMBL20283870 | 0.89 | ATR (0.80) | ATRGSK3BPRKDC | |
| SCHEMBL16070049 | 0.83 | ATR (0.63) | ATRGSK3BPRKDCKCNH2 | |
| SCHEMBL3048753 | 0.82 | ATR (0.67) | ATRGSK3BPRKDC | |
| SCHEMBL16093104 | 0.81 | ATR (0.58) | ATRGSK3BPRKDC | |
| SCHEMBL13345797 | 0.81 | ATR (0.79) | ATRPRKDCKCNH2 | |
| SCHEMBL13138284 | 0.81 | ATR (0.67) | ATRGSK3BPRKDCKCNH2 | |
| SCHEMBL2484306 | 0.81 | ATR (0.80) | ATRGSK3BPRKDC | |
| SCHEMBL24248210 | 0.80 | ATR (0.71) | ATRGSK3BPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150051187-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2015-02-19 | — | — | US | disclosed |
| US-20150030539-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | PIRAMAL IMAGING SA (CH) | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150030539-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | PMP22, MEN1, VHL | ATR 2406/4885GSK3B 1449/4885PRKDC 4071/4885 |
| US-20150051187-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ATR 1/4885GSK3B 216/4885PRKDC 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.